Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AMGEN INCAMGN · Entity 2832 | Exe VP, Global Commercial Ops | April 28, 2010 | April 30, 2010 |
| Fresh Tracks Therapeutics, Inc.VICL · Entity 90076 | Director | May 23, 2018 | May 24, 2018 |
| NEUROCRINE BIOSCIENCES INCNBIX · Entity 2655 | Director | May 27, 2026 | May 29, 2026 |
| OTONOMY, INC.OTIC · Entity 116495 | Director | June 20, 2017 | July 14, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AMGEN INC
Report date April 28, 2010 · Filed April 30, 2010
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 131,889 |
Reported balance
After 2010-04-28 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2010-04-28 · Tax withholding · Disposed 1,401 · Balance 131,889 |
| Common StockSEC Table I · non-derivative | Direct | 130,488 |
Reported balance
After 2010-04-29 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2010-04-29 · Tax withholding · Disposed 1,401 · Balance 130,488 F1: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 6,000 RSUs which vest in two equal annual installments of 3,000 each commencing 4/29/2011; 9,000 RSUs which vest in three equal annual installments of 3,000 each commencing 4/28/2011; and 12,000 RSUs which vest in four equal installments of 3,000 each commencing 4/26/2011. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. |
| Common StockSEC Table I · non-derivative | IndirectBy 401(k) Plan | 2,717.7088 |
Reported balance
Holding disclosure · report date 2010-04-28 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 2,717.7088 F2: These are shares acquired under the Company's 401(k) Plan and represent interests in the Company's stock fund as of the date of this filing. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 6,000 RSUs which vest in two equal annual installments of 3,000 each commencing 4/29/2011; 9,000 RSUs which vest in three equal annual installments of 3,000 each commencing 4/28/2011; and 12,000 RSUs which vest in four equal installments of 3,000 each commencing 4/26/2011. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.
F2: These are shares acquired under the Company's 401(k) Plan and represent interests in the Company's stock fund as of the date of this filing.
Fresh Tracks Therapeutics, Inc.
Report date May 23, 2018 · Filed May 24, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Nonstatutory Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.67 · Expires 2028-05-22 | Direct | 6,500 |
Reported balance
After 2018-05-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-05-23 · Grant · Acquired 6,500 · Balance 6,500 F1: The date in this field is approximate. These options are exercisable at the date of the next annual meeting of stockholders. The date of the meeting has not been set, but is expected to occur in May 2019. |
Filing footnotes · ownership attribution and instrument terms
F1: The date in this field is approximate. These options are exercisable at the date of the next annual meeting of stockholders. The date of the meeting has not been set, but is expected to occur in May 2019.
NEUROCRINE BIOSCIENCES INC
Report date May 27, 2026 · Filed May 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restriced Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 2,567 |
Reported balance
After 2026-05-27 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-27 · Grant · Acquired 2,567 · Balance 2,567 F1: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting. F2: The RSUs will vest in full on May 27, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting.
F2: The RSUs will vest in full on May 27, 2027.
OTONOMY, INC.
Report date June 20, 2017 · Filed July 14, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.05 · Expires 2027-06-20 | Direct | 15,000 |
Reported balance
After 2017-06-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-06-20 · Grant · Acquired 15,000 · Balance 15,000 F1: The shares subject to the option vest in full on the date of the Issuer's next annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option vest in full on the date of the Issuer's next annual meeting of stockholders.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ALIGN TECHNOLOGY INC
Report date May 20, 2026 · Filed May 22, 2026
Section 16 reporting ended · disclosed 2026-05-22. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 5,036 |
Reported balance
After 2026-05-20 transaction · row 1
1 source rowRow 1 · 2026-05-20 · Exercise / conversion · Acquired 1,745 · Balance 5,036 |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-05-20 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-05-20 · Exercise / conversion · Disposed 1,745 · Balance 0 F1: 100% of the restricted stock units ("RSUs") granted on May 21, 2025 vested on May 20, 2026 and shares were delivered to the Reporting Person. |
| Common StockSEC Table I · non-derivative | IndirectBy Family Trust | 3,273 |
Reported balance
Holding disclosure · report date 2026-05-20 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 3,273 |
Filing footnotes · ownership attribution and instrument terms
F1: 100% of the restricted stock units ("RSUs") granted on May 21, 2025 vested on May 20, 2026 and shares were delivered to the Reporting Person.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 03, 2006 Filed Apr 4, 2006 21:35 UTC | AMGEN INC AMGN · Entity 2832 | GrantNQSO (Right to Buy) · Derivative | 63,609 | Not disclosed Strike: $71.88 | Not disclosed |
DisclosureSEC source: 0001181431-06-022148 · rrd113345.xml · derivative · entry 3 MORROW GEORGE J · CIK 0001068754 · Exe VP, Global Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,609 Underlying: Common Stock · 63,609 shares Expires 2013-04-03 F1 · price: Right to buy granted under the Company's Amended and Restated 1991 Equity Incentive Plan. F2 · derivative.exercise_date: The option becomes exercisable annually as follows: 16,250 shares on April 3, 2007; 16,250 shares on April 3, 2008; 16,250 shares on April 3, 2009; and 14,859 shares on April 3, 2010. Read SEC document |
| April 03, 2006 Filed Apr 4, 2006 21:35 UTC | AMGEN INC AMGN · Entity 2832 | GrantISO (Right to Buy) · Derivative | 1,391 | Not disclosed Strike: $71.88 | Not disclosed |
DisclosureSEC source: 0001181431-06-022148 · rrd113345.xml · derivative · entry 2 MORROW GEORGE J · CIK 0001068754 · Exe VP, Global Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,391 Underlying: Common Stock · 1,391 shares Expires 2013-04-03 F1 · price: Right to buy granted under the Company's Amended and Restated 1991 Equity Incentive Plan. Read SEC document |
| July 25, 2005 Filed Jul 26, 2005 20:42 UTC | AMGEN INC AMGN · Entity 2832 | Exercise / conversionNQSO (Right to Buy) · Derivative | 80,000 | $61.67 Strike: $61.67 | $4,933,600.00 |
DisclosureSEC source: 0001181431-05-042089 · rrd86843.xml · derivative · entry 23 MORROW GEORGE J · CIK 0001068754 · Exe VP, Global Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,379 Underlying: Common Stock · 80,000 shares Expires 2008-07-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: (GJM 7/2/2001) The option is exercisable in four equal installments of 20,000 each beginning July 2, 2002 and a final installment of 18,379 shares on July 2, 2006. Read SEC document |
| July 25, 2005 Filed Jul 26, 2005 20:42 UTC | AMGEN INC AMGN · Entity 2832 | Exercise / conversionNQSO (Right to Buy) · Derivative | 193,336 | $60.00 Strike: $60.00 | $11,600,160.00 |
DisclosureSEC source: 0001181431-05-042089 · rrd86843.xml · derivative · entry 22 MORROW GEORGE J · CIK 0001068754 · Exe VP, Global Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 193,336 shares Expires 2008-01-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 25, 2005 Filed Jul 26, 2005 20:42 UTC | AMGEN INC AMGN · Entity 2832 | Exercise / conversionNQSO (Right to Buy) · Derivative | 29,999 | $38.36 Strike: $38.36 | $1,150,761.64 |
DisclosureSEC source: 0001181431-05-042089 · rrd86843.xml · derivative · entry 21 MORROW GEORGE J · CIK 0001068754 · Exe VP, Global Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,394 Underlying: Common Stock · 29,999 shares Expires 2009-07-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: (GJM 7/1/2002) The remaining option is exercisable as follows: 30,000 on July 1, 2006; and 27,394 shares on July 1, 2007. Read SEC document |
| July 25, 2005 Filed Jul 26, 2005 20:42 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 10,000 | $81.25 | $812,500.00 |
DisclosureSEC source: 0001181431-05-042089 · rrd86843.xml · nonDerivative · entry 20 MORROW GEORGE J · CIK 0001068754 · Exe VP, Global Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Read SEC document |
| July 25, 2005 Filed Jul 26, 2005 20:42 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 15,000 | $81.24 | $1,218,600.00 |
DisclosureSEC source: 0001181431-05-042089 · rrd86843.xml · nonDerivative · entry 19 MORROW GEORGE J · CIK 0001068754 · Exe VP, Global Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Read SEC document |
| July 25, 2005 Filed Jul 26, 2005 20:42 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 5,000 | $81.22 | $406,100.00 |
DisclosureSEC source: 0001181431-05-042089 · rrd86843.xml · nonDerivative · entry 18 MORROW GEORGE J · CIK 0001068754 · Exe VP, Global Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Read SEC document |
| July 25, 2005 Filed Jul 26, 2005 20:42 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 10,000 | $81.21 | $812,100.00 |
DisclosureSEC source: 0001181431-05-042089 · rrd86843.xml · nonDerivative · entry 17 MORROW GEORGE J · CIK 0001068754 · Exe VP, Global Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Read SEC document |
| July 25, 2005 Filed Jul 26, 2005 20:42 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 10,000 | $81.21 | $812,100.00 |
DisclosureSEC source: 0001181431-05-042089 · rrd86843.xml · nonDerivative · entry 16 MORROW GEORGE J · CIK 0001068754 · Exe VP, Global Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Read SEC document |
| July 25, 2005 Filed Jul 26, 2005 20:42 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 73,335 | $81.20 | $5,954,802.00 |
DisclosureSEC source: 0001181431-05-042089 · rrd86843.xml · nonDerivative · entry 15 MORROW GEORGE J · CIK 0001068754 · Exe VP, Global Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Read SEC document |
| July 25, 2005 Filed Jul 26, 2005 20:42 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 10,000 | $81.15 | $811,500.00 |
DisclosureSEC source: 0001181431-05-042089 · rrd86843.xml · nonDerivative · entry 14 MORROW GEORGE J · CIK 0001068754 · Exe VP, Global Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,335 Read SEC document |
| July 25, 2005 Filed Jul 26, 2005 20:42 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 13,000 | $81.10 | $1,054,300.00 |
DisclosureSEC source: 0001181431-05-042089 · rrd86843.xml · nonDerivative · entry 13 MORROW GEORGE J · CIK 0001068754 · Exe VP, Global Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,335 Read SEC document |
| July 25, 2005 Filed Jul 26, 2005 20:42 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 22,000 | $81.09 | $1,783,980.00 |
DisclosureSEC source: 0001181431-05-042089 · rrd86843.xml · nonDerivative · entry 12 MORROW GEORGE J · CIK 0001068754 · Exe VP, Global Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,335 Read SEC document |
| July 25, 2005 Filed Jul 26, 2005 20:42 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 39,000 | $81.07 | $3,161,730.00 |
DisclosureSEC source: 0001181431-05-042089 · rrd86843.xml · nonDerivative · entry 11 MORROW GEORGE J · CIK 0001068754 · Exe VP, Global Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,335 Read SEC document |
| July 25, 2005 Filed Jul 26, 2005 20:42 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 15,000 | $81.05 | $1,215,750.00 |
DisclosureSEC source: 0001181431-05-042089 · rrd86843.xml · nonDerivative · entry 10 MORROW GEORGE J · CIK 0001068754 · Exe VP, Global Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 217,335 Read SEC document |
| July 25, 2005 Filed Jul 26, 2005 20:42 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 28,000 | $81.02 | $2,268,560.00 |
DisclosureSEC source: 0001181431-05-042089 · rrd86843.xml · nonDerivative · entry 9 MORROW GEORGE J · CIK 0001068754 · Exe VP, Global Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 232,335 Read SEC document |
| July 25, 2005 Filed Jul 26, 2005 20:42 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 10,000 | $81.01 | $810,100.00 |
DisclosureSEC source: 0001181431-05-042089 · rrd86843.xml · nonDerivative · entry 8 MORROW GEORGE J · CIK 0001068754 · Exe VP, Global Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 260,335 Read SEC document |
| July 25, 2005 Filed Jul 26, 2005 20:42 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 10,000 | $81.00 | $810,000.00 |
DisclosureSEC source: 0001181431-05-042089 · rrd86843.xml · nonDerivative · entry 7 MORROW GEORGE J · CIK 0001068754 · Exe VP, Global Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 270,335 Read SEC document |
| July 25, 2005 Filed Jul 26, 2005 20:42 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 3,000 | $80.99 | $242,970.00 |
DisclosureSEC source: 0001181431-05-042089 · rrd86843.xml · nonDerivative · entry 6 MORROW GEORGE J · CIK 0001068754 · Exe VP, Global Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 280,335 Read SEC document |
| July 25, 2005 Filed Jul 26, 2005 20:42 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 25,000 | $80.99 | $2,024,750.00 |
DisclosureSEC source: 0001181431-05-042089 · rrd86843.xml · nonDerivative · entry 5 MORROW GEORGE J · CIK 0001068754 · Exe VP, Global Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 283,335 Read SEC document |
| July 25, 2005 Filed Jul 26, 2005 20:42 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 5,000 | $80.93 | $404,650.00 |
DisclosureSEC source: 0001181431-05-042089 · rrd86843.xml · nonDerivative · entry 4 MORROW GEORGE J · CIK 0001068754 · Exe VP, Global Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 308,335 Read SEC document |
| July 25, 2005 Filed Jul 26, 2005 20:42 UTC | AMGEN INC AMGN · Entity 2832 | Exercise / conversionCommon Stock | 80,000 | $61.67 | $4,933,600.00 |
DisclosureSEC source: 0001181431-05-042089 · rrd86843.xml · nonDerivative · entry 3 MORROW GEORGE J · CIK 0001068754 · Exe VP, Global Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 313,335 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 25, 2005 Filed Jul 26, 2005 20:42 UTC | AMGEN INC AMGN · Entity 2832 | Exercise / conversionCommon Stock | 193,336 | $60.00 | $11,600,160.00 |
DisclosureSEC source: 0001181431-05-042089 · rrd86843.xml · nonDerivative · entry 2 MORROW GEORGE J · CIK 0001068754 · Exe VP, Global Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 233,335 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 25, 2005 Filed Jul 26, 2005 20:42 UTC | AMGEN INC AMGN · Entity 2832 | Exercise / conversionCommon Stock | 29,999 | $38.36 | $1,150,761.64 |
DisclosureSEC source: 0001181431-05-042089 · rrd86843.xml · nonDerivative · entry 1 MORROW GEORGE J · CIK 0001068754 · Exe VP, Global Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,999 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 15, 2005 Filed Mar 17, 2005 00:41 UTC | AMGEN INC AMGN · Entity 2832 | GrantNQSO (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $58.61 | $0.00 |
DisclosureSEC source: 0001181431-05-017346 · rrd72675.xml · derivative · entry 1 MORROW GEORGE J · CIK 0001068754 · Exe VP, Global Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2012-03-15 F1 · derivative.exercise_date: (03.15.05) The option becomes exercisable annually in four equal installments beginning on March 15, 2006. Read SEC document |
| November 23, 2004 Filed Nov 23, 2004 22:52 UTC | AMGEN INC AMGN · Entity 2832 | Exercise / conversionNQSO (Right to Buy) · Derivative | 59,998 | $0.00 Strike: $38.36 | $0.00 |
DisclosureSEC source: 0001181431-04-054794 · rrd59120.xml · derivative · entry 6 MORROW GEORGE J · CIK 0001068754 · Exe VP, Global Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,393 Underlying: Common Stock · 59,998 shares Expires 2009-07-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: (GJM-07/02-NQSO) The option becomes exercisable for 29,999 shares on July 1, 2003; 29,999 shares on July 1, 2004; 29,999 shares on July 1, 2005; 30,000 shares on July 1, 2006; 27,394 shares on July 1, 2007; respectively. Read SEC document |
| November 23, 2004 Filed Nov 23, 2004 22:52 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 15,000 | $59.55 | $893,250.00 |
DisclosureSEC source: 0001181431-04-054794 · rrd59120.xml · nonDerivative · entry 5 MORROW GEORGE J · CIK 0001068754 · Exe VP, Global Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Read SEC document |
| November 23, 2004 Filed Nov 23, 2004 22:52 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 15,000 | $59.57 | $893,550.00 |
DisclosureSEC source: 0001181431-04-054794 · rrd59120.xml · nonDerivative · entry 4 MORROW GEORGE J · CIK 0001068754 · Exe VP, Global Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Read SEC document |
| November 23, 2004 Filed Nov 23, 2004 22:52 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 15,000 | $59.60 | $894,000.00 |
DisclosureSEC source: 0001181431-04-054794 · rrd59120.xml · nonDerivative · entry 3 MORROW GEORGE J · CIK 0001068754 · Exe VP, Global Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Read SEC document |
| November 23, 2004 Filed Nov 23, 2004 22:52 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 14,998 | $59.63 | $894,330.74 |
DisclosureSEC source: 0001181431-04-054794 · rrd59120.xml · nonDerivative · entry 2 MORROW GEORGE J · CIK 0001068754 · Exe VP, Global Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 Read SEC document |
| November 23, 2004 Filed Nov 23, 2004 22:52 UTC | AMGEN INC AMGN · Entity 2832 | Exercise / conversionCommon Stock | 59,998 | $38.36 | $2,301,523.28 |
DisclosureSEC source: 0001181431-04-054794 · rrd59120.xml · nonDerivative · entry 1 MORROW GEORGE J · CIK 0001068754 · Exe VP, Global Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,998 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 15, 2004 Filed Mar 16, 2004 23:27 UTC | AMGEN INC AMGN · Entity 2832 | GrantNQSO (Right to Buy) · Derivative | 73,319 | $0.00 Strike: $59.48 | $0.00 |
DisclosureSEC source: 0001181431-04-016012 · rrd36905.xml · derivative · entry 2 MORROW GEORGE J · CIK 0001068754 · Exe VP, Global Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,319 Underlying: Common Stock · 73,319 shares Expires 2011-03-15 F1 · derivative.exercise_date: (3.15.04) The option becomes exercisable in five as nearly equal annual installments as possible,beginning on March 15,2005. Read SEC document |
| March 15, 2004 Filed Mar 16, 2004 23:27 UTC | AMGEN INC AMGN · Entity 2832 | GrantISO (Right to Buy) · Derivative | 1,681 | $0.00 Strike: $59.48 | $0.00 |
DisclosureSEC source: 0001181431-04-016012 · rrd36905.xml · derivative · entry 1 MORROW GEORGE J · CIK 0001068754 · Exe VP, Global Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,681 Underlying: Common Stock · 1,681 shares Expires 2011-03-15 Read SEC document |
| July 01, 2003 Filed Jul 2, 2003 20:24 UTC | AMGEN INC AMGN · Entity 2832 | GrantNQSO (Right to Buy) · Derivative | 148,482 | $0.00 Strike: $65.85 | $0.00 |
DisclosureSEC source: 0001181431-03-012809 · rrd11638.xml · derivative · entry 2 MORROW GEORGE J · CIK 0001068754 · Exe VP, Global Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,482 Underlying: Common Stock · 148,482 shares Expires 2010-07-01 F2 · price: 0 F1 · derivative.exercise_date: (GJM-07/03-NQSO) The option becomes exercisable for 30,000 shares on July 1, 2004; 30,000 shares on July 1, 2005; 30,000 shares on July 1, 2006; 30,000 shares on July 1, 2007; and 28,482 shares on July 1, 2008, respectively. Read SEC document |
| July 01, 2003 Filed Jul 2, 2003 20:24 UTC | AMGEN INC AMGN · Entity 2832 | GrantISO (Right to Buy) · Derivative | 1,518 | $0.00 Strike: $65.85 | $0.00 |
DisclosureSEC source: 0001181431-03-012809 · rrd11638.xml · derivative · entry 1 MORROW GEORGE J · CIK 0001068754 · Exe VP, Global Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,518 Underlying: Common Stock · 1,518 shares Expires 2010-07-01 F2 · price: 0 Read SEC document |
| October 26, 2000 Filed Oct 29, 2020 00:17 UTC | ALIGN TECHNOLOGY INC ALGN · Entity 3488 | SaleCommon Stock | 2,727 | $468.78 | $1,278,366.88 |
DisclosureSEC source: 0001209191-20-056152 · doc4.xml · nonDerivative · entry 4 MORROW GEORGE J · CIK 0001068754 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,478 F4 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $468.02 to $470.15, inclusive. The reporting person undertakes to provide Align Technology, Inc., any security holder of Align Technology, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.